Amneal Pharmaceuticals Files 8-K on Financials
Ticker: AMRX · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1723128
Sentiment: neutral
Topics: financial-condition, results-of-operations, disclosure
Related Tickers: AMRX
TL;DR
Amneal dropped an 8-K detailing financials and operations as of March 1, 2024.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on March 1, 2024, to report on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company's principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
Why It Matters
This filing provides investors with crucial updates on Amneal Pharmaceuticals' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing and does not contain information that inherently increases risk.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- March 1, 2024 (date) — Date of Report
- 400 Crossing Blvd, Bridgewater, NJ 08807 (address) — Principal executive offices
- 001-38485 (company_id) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Amneal Pharmaceuticals, Inc.'s results of operations and financial condition, as well as to include Regulation FD disclosures and financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on March 1, 2024.
What is Amneal Pharmaceuticals, Inc.'s principal executive office address?
Amneal Pharmaceuticals, Inc.'s principal executive office is located at 400 Crossing Blvd, Bridgewater, NJ 08807.
What is the Commission File Number for Amneal Pharmaceuticals, Inc.?
The Commission File Number for Amneal Pharmaceuticals, Inc. is 001-38485.
What is the IRS Employer Identification Number for Amneal Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Amneal Pharmaceuticals, Inc. is 93-4225266.
Filing Stats: 701 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-03-01 06:13:05
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
Filing Documents
- amrx-20240301.htm (8-K) — 28KB
- amrx-q42023ex991.htm (EX-99.1) — 543KB
- amneal.jpg (GRAPHIC) — 3KB
- 0001723128-24-000007.txt ( ) — 737KB
- amrx-20240301.xsd (EX-101.SCH) — 2KB
- amrx-20240301_lab.xml (EX-101.LAB) — 24KB
- amrx-20240301_pre.xml (EX-101.PRE) — 12KB
- amrx-20240301_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 1, 2024, Amneal Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, March 1, 2024, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 743629. A replay of the conference call will be posted shortly after the call and will be available for seven days. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=52762. The information in this report furnished pursuant to Item 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit No. Description 99.1 Press release issued March 1, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 1, 2024 AMNEAL PHARMACEUTICALS, INC. By: /s/ Anastasios Konidaris Name: Anastasios Konidaris Title: Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)